|
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
It is now apparent that deregulation of beta-catenin signaling is an important event in the genesis of a number of malignancies, such as colon cancer, melanoma, hepatocellular carcinoma, ovarian cancer, endometrial cancer, medulloblastoma pilomatricomas, and prostate cancer. beta-catenin mutations appear to be a crucial step in the progression of a subset of these cancers, suggesting an important role in the control of cellular proliferation or cell death.
|
10580987 |
1999 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
PBK/TOPK enhances aggressive phenotype in prostate cancer via β-catenin-TCF/LEF-mediated matrix metalloproteinases production and invasion.
|
25909225 |
2015 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Heightened expression of the Trop2 intracellular domain promotes stem/progenitor self-renewal through signaling via β-catenin and is sufficient to initiate precursor lesions to prostate cancer in vivo.
|
23070813 |
2012 |
|
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, ZNF433 was the binding partner of beta-catenin and activated beta-catenin/TCF signaling in prostate cancer.
|
30774387 |
2019 |
|
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Alpha-methylacyl-CoA racemase (AMACR) is highly overexpressed in prostate cancer (PCa) and its transcriptional regulators include various transcription factors and CTNNB1/β-catenin.
|
28741117 |
2017 |
|
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
For the first time we provide experimental evidence that the C-terminus of p53 plays an important role in the down-regulation of beta-catenin-mediated TCF-signalling in PCa-cell lines possibly via p53 transrepressional function.
|
17929268 |
2007 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Roles and regulation of Wnt signaling and beta-catenin in prostate cancer.
|
16023783 |
2006 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Moreover, we detected the endogenous protein complex containing ICAT, AR, and β-catenin in prostate cancer cells using immunoprecipitation assays.
|
21885566 |
2011 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Because we had demonstrated that PrKD1 is the only known kinase to phosphorylate threonine 120 (T120) of beta-catenin in prostate cancer resulting in increased nuclear beta-catenin, we explored the role of beta-catenin in gene regulation of <i>PrKD1</i>.
|
29108267 |
2017 |
|
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Ten genes were expressed differently (false discovery rate, 0.05) in MDA prostate cancer 118b cells with downregulated β-catenin.
|
22298898 |
2012 |
|
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The β-catenin:TCF interaction plays a critical role in the Wnt signaling pathway which is over-activated in multiple cancers, including prostate cancer.
|
30352998 |
2018 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
This study establishes the functional significance of combined dysregulation of PKD1 and E-cadherin in PC and that their effect on cell growth is mediated by beta-catenin.
|
17979146 |
2008 |
|
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
As a translational research tool, OCP identified adaptive CTNNB1 amplifications/mutations in treated prostate cancers.
|
25925381 |
2015 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
β-catenin has also been reported to form complex with AR and thus augment AR signaling in PCa.
|
31027362 |
2019 |
|
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In addition, DVL1 and beta-catenin protein expression was evaluated with a new validated set of 20 prostate cancers.
|
16457155 |
2006 |
|
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Although evidence of abnormal activation of the Wnt pathway in prostate cancer has been demonstrated by several groups, APC and beta-catenin mutations are infrequent.
|
18514389 |
2009 |
|
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Abnormal expression of Wnt5a and beta-catenin was observed in 27 (28%) and 49 (50%) of 98 prostate cancer cases, respectively, by immunohistochemical analyses.
|
20101234 |
2010 |
|
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Given its oncogenic activity and connection to human cancer, we examined the beta-catenin gene and its expression in prostate cancer.
|
11102958 |
2000 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Pharmacological inhibition of β-catenin nuclear translocation using compounds ICG001 and IWR-1 restored HLEC tight-junction integrity and inhibited prostate cancer cell transendothelial migration in vitro and lung metastasis in vivo.
|
29755115 |
2018 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Wnt is a complex signaling pathway whose endpoint involves activation of transcription from LEF-1/TCF transcription factors and it is known to be involved in the development and progression of numerous human epithelial tumors including prostate cancer. beta-catenin protein, a particularly critical molecular component of canonical Wnt signaling is now known to promote androgen signaling through its ability to bind to the AR protein in a ligand-dependent fashion and to enhance the ability of liganded AR to activate transcription of androgen-regulated genes.
|
16741972 |
2006 |
|
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, targeting clinically significant PCa with high levels of δ-catenin with anti-androgen and anti β-catenin combination therapy may prevent progression of the disease to a castration-resistant state and, thus, represents a promising therapeutic strategy.
|
29849951 |
2018 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
In addition, CDC20 combined with CD44 or β-catenin can serve as an important indicator for prognosis of patients with prostate cancer.
|
30904606 |
2019 |
|
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Beta-catenin mutations in human prostate cancer.
|
9635571 |
1998 |
|
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In this study, we show that transfection of human prostate cancer cells (LNCaP) with PCDH-PC or culture of these cells in androgen-free medium (a condition that up-regulates PCDH-PC expression) activates wnt signaling as assessed by nuclear accumulation of beta-catenin, increased expression of luciferase from a reporter vector promoted by Tcf binding elements and increased expression of wnt target genes.
|
15958572 |
2005 |
|
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Therefore, targeting β-catenin expression could be a useful approach to treating prostate cancer.
|
30819007 |
2019 |